Savior Lifetec Overview
Savior Lifetec (4167.TWO) has a ROE of 23.47%, above the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow23.47%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 4167.TWO is 23.47%. That is above the Healthcare sector average of 20.77%. Investors often review this figure alongside Savior Lifetec's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 4167.TWO currently prints 23.47% for ROE, while the sector average sits near 20.77%. That is roughly 13.0% above the sector mean. Large gaps often invite a closer look at Savior Lifetec's growth, margins, and balance sheet.
Return on Equity shows how effectively Savior Lifetec converts resources into returns. At 23.47%, 4167.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 4167.TWO's ROE (23.47%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Savior Lifetec's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
